The significant investment in U.S. manufacturing plants by Eli Lilly is a strategic move to mitigate risks associated with potential tariffs on drug imports. This could enhance domestic production capabilities and reduce reliance on imports, potentially boosting investor confidence and positively impacting the stock price.